MediWound Ltd. Updates on Commercial Production
Ticker: MDWD · Form: 6-K · Filed: Jan 8, 2025 · CIK: 1593984
| Field | Detail |
|---|---|
| Company | Mediwound Ltd. (MDWD) |
| Form Type | 6-K |
| Filed Date | Jan 8, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, commercial-production
TL;DR
MediWound dropped a 6-K on Jan 8th with a presentation on commercial production. Check their site.
AI Summary
On January 8, 2025, MediWound Ltd. published a presentation on its website. This presentation highlighted the company's commercial production activities and provided an update on its business operations. The filing is a Form 6-K, which is a report of foreign private issuers submitted to the SEC.
Why It Matters
This filing provides investors with a recent update on MediWound's commercial activities, offering insights into the company's operational progress and market presence.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer activities and does not contain significant new financial or strategic information that would inherently increase risk.
Key Players & Entities
- MediWound Ltd. (company) — Registrant
- January 8, 2025 (date) — Filing and presentation date
FAQ
What type of report is this filing?
This filing is a Form 6-K, which is a Report of Foreign Private Issuer.
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report on the month of January 2025 and includes a presentation highlighting MediWound Ltd.'s commercial production.
When was the presentation published?
The presentation was published on January 8, 2025.
Where can investors find the presentation?
The presentation was published on the Company's website.
What is the company's principal executive office address?
The company's principal executive offices are located at 42 Hayarkon Street, Yavne, 8122745, Israel.
Filing Stats: 424 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2025-01-08 08:00:36
Filing Documents
- zk2532522.htm (6-K) — 12KB
- exhibit_99-1.htm (EX-99.1) — 46KB
- image_001.jpg (GRAPHIC) — 435KB
- image_002.jpg (GRAPHIC) — 883KB
- image_003.jpg (GRAPHIC) — 182KB
- image_004.jpg (GRAPHIC) — 166KB
- image_005.jpg (GRAPHIC) — 192KB
- image_007.jpg (GRAPHIC) — 145KB
- image_008.jpg (GRAPHIC) — 138KB
- image_009.jpg (GRAPHIC) — 86KB
- image_010.jpg (GRAPHIC) — 183KB
- image_011.jpg (GRAPHIC) — 249KB
- image_012.jpg (GRAPHIC) — 148KB
- image_013.jpg (GRAPHIC) — 142KB
- image_014.jpg (GRAPHIC) — 166KB
- image_015.jpg (GRAPHIC) — 246KB
- image_016.jpg (GRAPHIC) — 146KB
- image_017.jpg (GRAPHIC) — 222KB
- image_018.jpg (GRAPHIC) — 165KB
- image_019.jpg (GRAPHIC) — 156KB
- image_020.jpg (GRAPHIC) — 296KB
- image_021.jpg (GRAPHIC) — 182KB
- image_022.jpg (GRAPHIC) — 193KB
- image_023.jpg (GRAPHIC) — 135KB
- image_024.jpg (GRAPHIC) — 223KB
- image_025.jpg (GRAPHIC) — 226KB
- image_026.jpg (GRAPHIC) — 174KB
- image_027.jpg (GRAPHIC) — 179KB
- image_028.jpg (GRAPHIC) — 404KB
- image_029.jpg (GRAPHIC) — 137KB
- p6.jpg (GRAPHIC) — 100KB
- 0001178913-25-000059.txt ( ) — 8737KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant's name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __ CONTENTS On January 8, 2025, MediWound Ltd. (the "Company") published a presentation on its website, highlighting its commercial product, its clinical products as well as certain estimates and projections as to expected future financial results and information. The presentation can be accessed on the Company's website at www.mediwound.com and is also furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this "Form 6-K"). The contents of the foregoing website are not a part of this Form 6-K. The information contained in the presentation is provided as of January 8, 2025. The Company does not assume any obligation to update the presentation in the future or revise any forward-looking statements to reflect actual future events or developments. The furnishing of the materials related to the presentation is not an admission as to the materiality of any information contained in those materials. The content of the presentation is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022 and August 15, 2023 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997, respectively) and on Form F-3 filed with the SEC on May 25, 2022 and August 29, 2024 (Registration Nos. 333-265203 and 333-281843, respectively). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MEDIWOUND LTD. Date: January 8, 2025 By: /s/ Hani Luxenburg Name: Hani Luxenburg Title: Chief Financial Officer EXHIBIT INDEX The following exhibit is filed as part of this Form 6-K: Exhibit Description 99.1 Corporate Presentation of MediWound Ltd. dated January 2025.